Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2612 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2009  |  Volume : 20  |  Issue : 3  |  Page : 392-397
Spironolactone in chronic hemodialysis patients improves cardiac function


1 Division of Nephrology, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran
2 Division of Cardiology, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran
3 Division of Students of Medicine, Department of Internal Medicine, Isfahan School of Medicine, Isfahan, Iran

Correspondence Address:
Shahram Taheri
Department of Internal Medicine, St. Al-Zahra Hospital, Soffeh Ave., Isfahan
Iran
Login to access the Email id


PMID: 19414940

Rights and Permissions

We performed this study to assess whether low dose spironolactone could be admi­nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio­vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro­nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi­ronolactone after each dialysis session within six months, and the rest received a placebo. Echo­cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi­ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5435    
    Printed164    
    Emailed0    
    PDF Downloaded1357    
    Comments [Add]    
    Cited by others 12    

Recommend this journal